Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, January 1998, p. 91-97, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Immunofluorescence Microscopy and Flow Cytometry Characterization
of Chemical Induction of Latent Epstein-Barr Virus
Hal B.
Jenson,1,2,*
George M.
Grant,3
Yasmin
Ench,1
Patty
Heard,1
Charles A.
Thomas,2
Susan G.
Hilsenbeck,4 and
Mary
Pat
Moyer2,5
Departments of
Pediatrics,1
Microbiology,2
Periodontics,3
Medicine,4 and
Surgery,5 The University of Texas
Health Science Center at San Antonio, San Antonio, Texas
Received 19 June 1997/Returned for modification 20 August
1997/Accepted 26 September 1997
 |
ABSTRACT |
The effects of chemical induction of latent Epstein-Barr virus
(EBV) with 12-O-tetradecanoyl phorbol-13-acetate (TPA) and n-butyrate on cell viability and induction of latent EBV in
Raji and X50-7 B lymphocytes, indicated by expression of the diffuse component of the EBV early antigen (EA-D), were measured by visual immunofluorescence microscopy (of both viable and nonviable cells) and
fluorescence-activated cell sorter (FACS) flow cytometry (of viable
cells only). Cell viability at 4 days decreased moderately for treated
Raji cells (9 to 37%, compared to 55 to 69% for untreated cells) and
markedly for X50-7 cells (1-32% compared to 35-44% in untreated
cells). The highest EA-D levels in viable cells occurred in Raji cells
treated with both TPA and n-butyrate and untreated X50-7
cells. TPA and n-butyrate acted synergistically to induce latent EBV, resulting in increased levels of EA-D production in Raji
cells and cell death in X50-7 cells. Methodological differences including the ability to detect antigen in only viable cells by FACS
flow cytometry accounted for the higher levels of EA-D observed by FACS
analysis compared to the levels observed by immunofluorescence microscopy. FACS analysis may be more objective and reproducible than
immunofluorescence microscopy for the detection of EBV induction and also permits viral protein expression to be distinguished in the
subpopulation of viable cells.
 |
INTRODUCTION |
Epstein-Barr virus (EBV) is a human
gamma herpesvirus that immortalizes human B lymphocytes and that
establishes lifelong infection in the host. In cell culture, EBV may be
maintained in vitro in B lymphocytes in perpetuity predominantly as a
latent infection with little or no viral replication or with continued production of mature virus at low levels. Chemicals known to induce latent EBV to undergo lytic replication include phorbol esters, including 12-O-tetradecanoyl phorbol-13-acetate (TPA)
(50), a direct activator of protein kinase C
(18); n-butyrate (21, 28); halogenated
pyrimidines such as 5-iododeoxyuridine (14, 16); and
nitrosamines (8). The effects of phorbol esters are mediated
by protein kinase C activation of the
c-jun-c-fos interaction with AP-1 binding sites
upstream of promoters of the BZLF1 and BRLF1 immediate-early virus
genes (13, 24, 25). Depending on the protein studied, TPA
and n-butyrate demonstrate inducer-dependent, cell
line-dependent, and protein-specific differences and act in an additive
or synergistic manner (1, 7, 31, 40). TPA and
n-butyrate induce EBV by different mechanisms, with a peak
effect between 1 and 4 days (7, 31, 40). Latent EBV may also
be induced by anti-immunoglobulin (42, 44) as well as by
superinfection with virus from the P3HR-1 EBV cell line and cell clones
of P3HR-1 containing het (heterogeneous)-defective EBV genomes
(10).
Several distinct EBV-associated antigen systems and their corresponding
antibodies have been characterized and are classified by the phase of
the viral replicative cycle during which they are expressed
(20). The immediate-early genes (BZLF1, BRLF1, and BI'LF4)
are followed sequentially by expression of proteins of the early
antigen (EA) complex, viral DNA replication, production of late
antigens (e.g., viral capsid antigen), and subsequent cell death with
the release of mature virions. The EA complex consists of several viral
proteins expressed within the cell and is divided into two components,
diffuse (EA-D) and restricted (EA-R), on the basis of cellular
localization (after fixation) and susceptibility to denaturation: EA-D
is found in both the nucleus and the cytoplasm and is stable in
acetone, methanol, and ethanol, and EA-R is found only in the cytoplasm
and is stable in acetone but is denatured by methanol or ethanol
(19). The EA-D antigen is composed of two moderately
abundant nuclear proteins: a 47- to 52-kDa protein transcribed from the
BMRF1 open reading frame that is an accessory subunit of the EBV DNA
polymerase catalytic subunit that is transcribed from BALF5 (22,
45) and a 44- to 50-kDa protein transcribed from the BSLF2 and
BMLF1 open reading frames that is a transactivator of other early EBV
genes (9, 47).
The Raji cell line, an EBV genome-positive Burkitt's lymphoma cell
line, harbors approximately 50 to 60 EBV genome equivalents per cell
(30, 36). This nonproducer cell line is particularly informative in the study of activation of latent EBV because of an
intrinsic block, after expression of EAs, that completely inhibits progression to viral DNA synthesis and late EBV gene expression (32, 43). This block is due to two deletions in the
endogenous EBV genome from Raji cells (17, 35, 38) compared
to the EBV genome from B95-8 cells (3). A 3.5-kb deletion of
BamHI-E results in the complete elimination of BERF4
(EBNA3C) and BZLF2 from EBV in B95-8 cells. A 2.9-kb deletion in
BamHI-A removes the complete BALF1 and BARF1 and the N
terminus of BALF2, the major EBV DNA binding protein, from EBV in B95-8
cells (48). The BALF2 deletion is responsible for the
inability of EBV in Raji cells to complete replication following the
induction of latent virus (11). Following chemical induction
Raji cells show signs of differentiation into plasma cells but without
the morphological changes of EBV lytic replication (1, 2).
The late EBV genes are expressed in Raji cells only after lytic
induction with P3HR-1 virus containing defective virions of EBV
(29) via a mechanism of induction different from the
mechanism of chemical induction (24). In contrast to the EBV
harbored by the Raji cell line, the EBV harbored by the X50-7 cell line
(46) is tightly latent but can be chemically induced to
complete virus replication resulting in cell death. The X50-7 cell line
was derived by immortalization of human umbilical cord lymphocytes with
EBV strain B95-8 (6). The sequence of the subsequent virus
from B95-8 cells but not that of virus from X50-7 cells has been shown
to have a 12-kb deletion (33) relative to the sequences of
other EBV strains. This eliminates one of the origins of lytic
replication (oriLyt) (15). The EBV in both Raji and X50-7
cells are subtype A (49).
Experimental detection of the expression of EBV antigens has
traditionally been done by immunofluorescence microscopy
(20), a time-consuming and labor-intensive method that
requires much experience for accurate interpretation of results. The
application of fluorescence-activated cell sorter (FACS) analysis or
flow cytometry offers semiautomation with the feasibility of counting many more cells than would be practical by conventional
immunofluorescence microscopy. In addition, immunofluorescence
microscopy necessitates pooling of the results for viable and nonviable
cells, whereas FACS analysis permits analysis of viable cells only. In
comparison with immunofluorescence microscopy, application of FACS
methods in the study of EBV gene expression may contribute to a more
precise quantitation of antigen expression, less subjective individual interpretation, greater reproducibility, and faster determination of
results, with the additional advantage that EBV gene expression can be
studied selectively in viable cells.
The studies described here evaluated the application of FACS analysis
to distinguishing viable from nonviable cells and compared FACS
analysis to conventional immunofluorescence microscopy for the study of
the induction of latent EBV and antigen production in Raji and X50-7
cells with two different chemical induction agents, TPA and
n-butyrate, alone and in combination. The effects of TPA and
n-butyrate on the induction of EA-D were compared by EBV
strain, chemical induction regimen, and the growth rate of the cells at
relatively slow or fast rates prior to chemical induction.
 |
MATERIALS AND METHODS |
Cell culture and virus induction.
The Raji lymphoid cell
line (ATCC CCL 86), an EBV-positive cell line derived from a Burkitt's
lymphoma (12, 37), and the X50-7 cell line (46),
a human umbilical lymphocyte line immortalized with the EBV from B95-8
cells (6), were used. The cells were maintained in RPMI 1640 medium containing 10% fetal bovine serum with 100 U of penicillin per
ml, 100 U of streptomycin per ml, 2.5 µg of amphotericin B per ml,
and 2 mM glutamine at 37°C in a humidified atmosphere with 5%
CO2. Raji and B95-8 cells show a lag in growth for
approximately 24 h after splitting, followed by exponential growth
peaking at 5 days and, finally, a subsequent decrease in the cell count
(4, 5). For these studies two subpopulations of Raji and
X50-7 cells were maintained in 25-cm2 flasks for at least 2 weeks prior to chemical induction: cultures designated fast growing
were split 1:1 with fresh medium twice per week (1st and 4th days), and
cultures designated slow growing were split 1:1 with fresh medium once
per week.
Chemical induction of EBV was initiated 24 h after splitting the
cultures by the addition to the growth medium of TPA (Sigma, St. Louis,
Mo.) at 20 ng/ml (10 µg/ml in ethanol), n-butyrate (Sigma)
at 4 mM (11 mg/ml in water), or both compounds at the same
concentrations used individually. The cells were harvested for analysis
at 2 and 4 days after induction.
Immunofluorescence microscopy.
The cells were washed three
times with phosphate-buffered saline (PBS), resuspended to a
concentration of 10,000 cells per 10 ml, prepared as cell smears on
eight-well microscope slides (Carlson Scientific, Peotone, Ill.), and
allowed to air dry for 1 h. Cell smears were fixed with prechilled
acetone for 4 min and were allowed to air dry. Cells smears were
stained for EA-D with 20 µl of mouse immunoglobulin G1 (IgG1)
monoclonal antibody (DuPont, Billerica, Mass.) against EA-D
(34) for 60 min at 37°C in a humidified chamber, rinsed
twice in PBS for 10 min, stained with goat anti-mouse IgG (heavy and
light chain specific)-fluorescein isothiocyanate (FITC)-conjugated
antibody (Boehringer Mannheim, Indianapolis, Ind.) diluted 1:20 in PBS
with 0.002% Evans blue counterstain, rinsed twice in PBS for 10 min,
dipped in distilled water, and allowed to air dry. A coverslip was
applied with glycerol-PBS (9:1; pH 8.5) as the mounting medium. A total
of approximately 1,000 cells were counted by visual microscopy with a
Zeiss epifluorescence microscope and were recorded as fluorescing or
nonfluorescing.
Flow cytometry.
Cells were fixed and stained by using an
adaptation of methanol fixation that allows for flow cytometry analysis
(26). Cells were washed three times with PBS, fixed by
resuspension in 1 ml of 100% methanol at 4°C for 15 min, washed once
with PBS, and washed twice with a FACS buffer (PBS containing 0.5%
bovine serum albumin and 0.01% NaN3). Induction of EBV
EA-D was detected by using at 100 µg/ml (diluted in PBS) the same
mouse IgG1 monoclonal antibody against EA-D (DuPont) described above.
The cells were stained with 50 µl of anti-EA-D antibody for 30 min at
37°C. The cells were rinsed three times with FACS buffer and were
counterstained for 30 min at 37°C with goat anti-mouse IgG (heavy and
light chain)-FITC conjugated antibody (Boehringer Mannheim) diluted
1:20 with 0.001% Evans blue in PBS. The cells were rinsed three times
with FACS buffer and were resuspended in 0.5 ml of FACS buffer for FACS analysis.
Flow cytometry was performed by using a FACStar Plus (Becton Dickinson
Immunocytometry Systems, San Jose, Calif.) flow cytometer with an
argon-ion laser producing 200 mW of 488-nm light for excitation. The
principles of flow cytometry have been described previously (27). The percentage of viable cells in each cell sample was determined in a separate aliquot prior to fixation and permeabilization by using propidium iodide staining to identify dead cells. The fluorescence from the propidium iodide was measured through a 630/22-nm
bandpass filter. The fluorescence from the FITC (for EA-D) was measured
through a 530/30-nm bandpass filter (Oriel Optical, Stamford, Conn.).
The fixed cells were gated on the basis of forward-angle light-scatter
pulse height, forward-angle light scatter pulse width, and right-angle
light scatter pulse height to exclude small debris, cell fragments, and
cell aggregates. Single-parameter data were collected for 20,000 intact
viable cells by determination of forward- and right-angle light scatter for each experimental group (a total of 16 groups), and the data were
displayed as a cell frequency histogram over 512 channels.
The percentage of cells that expressed EA-D as determined by FACS
analysis was determined separately for each experimental group at the
log relative fluorescence intensity at which 1% of control cells
stained only with the secondary antibody (the FITC-conjugated goat
anti-mouse IgG) showed fluorescence. Additional control cells were
stained with mouse isotype-specific IgG1 monoclonal antibody followed
by goat anti-mouse IgG (heavy and light chain)-FITC conjugate antibody
to control for nonspecific immunoglobulin binding.
Statistical analysis.
FACS analysis data on the percentage
of viable cells and the percentage of viable cells expressing EA-D at 4 days after chemical induction (with or without TPA and with or
without n-butyrate) for cells growing at a slow rate and a
fast rate were analyzed by three-way analysis of variance (ANOVA) in
which the Raji or X50-7 cell type was included as a blocking factor and
TPA and n-butyrate were included as treatment factors.
Outcome data (percentage of viable cells and percentage of viable cells
expressing EA-D) were transformed by using arcsin
(
), a variance-stabilizing transformation
appropriate for percentages (41). ANOVA models included Raji
or X50-7 cell type, TPA, and n-butyrate as main effects and
an interaction for TPA and n-butyrate. Values predicted
on the basis of the model and 95% confidence intervals were
back-transformed (back-transformation = 100 · sin2 t) for purposes of graphical display
(t is a sample statistic from the transformed data
set).
 |
RESULTS |
None of the control cells demonstrated nonspecific binding
of immunoglobulin by direct immunofluorescence microscopy or FACS analysis.
Differences in cell viability and in the induction of latent EBV as
determined by the levels of expression of EA-D as a result of the
effects of TPA, n-butyrate, and both chemicals were found between EBV-infected Raji and X50-7 cells. The mean percentage of
viable cells was higher for untreated Raji cells (55 to 69%) than for
untreated X50-7 cells (35 to 44%), although the 95% confidence intervals overlapped. Untreated Raji cells had higher percentages of
viable cells than any group of treated Raji cells. Raji cells treated
with TPA alone exhibited intermediate viability, with slightly lower
viability in cells treated with n-butyrate alone, which was
minimally lower with both chemicals (Fig.
1). Regardless of a slow or a fast growth
rate, TPA significantly reduced viability (P = 0.001),
n-butyrate significantly reduced viability
(P = 0.0004), but the effect of the two chemicals
combined was not as great as that predicted from the effects of the
chemicals used individually (TPA × n-butyrate
interaction; P = 0.008). There was also a significant independent effect of growth rate, with uniformly lower rates of cell
viability for slowly growing Raji cells than for fast-growing Raji
cells (P = 0.003), regardless of the type of chemical
induction. For X50-7 cells, the maximal decrease in cell viability
occurred with n-butyrate with or without TPA.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Observed values (circles) and estimated means and 95%
confidence intervals (bars) for viability of Raji cells and X50-7 cells
growing at a slow rate and a fast rate following chemical induction of
latent EBV by TPA (20 ng/ml), n-butyrate (4 mM), or both
compounds measured by FACS analysis at 4 days. Complete viral
replication is constitutively inhibited in Raji cells (17, 35,
38), resulting in the accumulation of EA; the increased rates of
death for treated cells compared to that for untreated cells is the
result of the direct toxicity of TPA and n-butyrate (1,
2). Induction of EBV in X50-7 cells continues to complete viral
replication with resultant cell death; increased rates of death for
treated cells compared to that for untreated cells is the result of the
combination of chemical toxicity plus lytic viral replication. The
error bars for X50-7 cells are significantly larger because of the
reversal of the results (for slow or fast growth) for TPA treatment
alone compared to the results for all other groups (untreated and
treated Raji and X50-7 cells).
|
|
For Raji cells (Fig. 2) the highest level
of chemical induction of EA-D as determined by FACS analysis was at 4 days for induction with TPA plus n-butyrate (18.7 to
24.5%), and the level was much higher than the level obtained 2 days
after induction with either chemical alone (0.4 to 2.1%) or with both
chemicals (2.2 to 3.4%). Substantially higher levels of EA-D were
found in Raji cells at 4 days than at 2 days for all chemical
treatments (0.4 to 24.5% compared to 0.0 to 3.4%, respectively). EA-D
expression did not appear to differ by slow or fast growth rate at 2 days (2.2 and 3.4%, respectively) or at 4 days (24.5 and 18.7%,
respectively) (Fig. 3). Statistical
analysis showed that at 4 days, the levels of EA-D in Raji cells
treated with TPA or n-butyrate alone were statistically
similar to those in untreated cells (P > 0.46), while
the level of expression in cells treated with TPA plus
n-butyrate was significantly increased (P < 0.007) compared to those in all other groups (Fig.
4). There was not a clearly appreciable
difference in EA-D levels in Raji cells that grew slowly and those that
grew fast (P = 0.8).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of chemical induction of EBV in Raji cells and
X50-7 cells (both growing at a fast rate) with TPA (20 ng/ml),
n-butyrate (4 mM), and both chemicals at 4 days determined
by FACS analysis with an EBV EA-D antibody. Each plot represents 20,000 viable lymphocytes (nonviable cells were excluded from FACS analysis).
The percentage of cells that expressed EA-D by FACS analysis was
determined separately for each experimental group at the log relative
fluorescence intensity at which 1% of control cells stained only with
the secondary antibody (the FITC-conjugated goat anti-mouse IgG) showed
fluorescence. For Raji cells, slightly increased levels of expression
of EA-D are detectable with each chemical (0.6 to 2.2%) compared to
level of expression for untreated cells (0.3 to 0.6%), but the level
of EA-D expression is increased 8 to 48 times when both chemicals are
used compared to the level of EA-D expression after induction with
either chemical alone. For X50-7 cells, the highest levels of EA-D
expression detectable by FACS analysis (viable cells only) are those of
untreated cells (11.3 to 22.2%) compared to the level of expression
after treatment with either chemical alone (0.6 to 8.0%) or both
chemicals (0.2 to 1.4%).
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of rate of cell growth rate (slow or fast) on
chemical induction of EBV in Raji cells and X50-7 cells with the
combination of TPA (20 ng/ml) and n-butyrate (4 mM) at 2 and
4 days determined by FACS analysis with an EBV EA-D antibody. Each plot
represents 20,000 viable lymphocytes (nonviable cells were excluded
from FACS analysis). The percentage of cells that expressed EA-D by
FACS analysis was determined separately for each experimental group at
the log relative fluorescence intensity at which 1% of control cells
stained only with the secondary antibody (the FITC-conjugated goat
anti-mouse IgG) showed fluorescence. For Raji cells, the levels of EA-D
are similar for both slowly growing and fast-growing cells at 2 days
(2.1 and 3.4%, respectively) and at 4 days (28.5 and 18.3%,
respectively; P = 0.8). For X50-7 cells, the levels of
EA-D are also similar at 2 days for both slowly growing and
fast-growing cells (0.2 and 0.6%, respectively) and are slightly
higher at 4 days in cells growing at a fast rate than in cells growing
at a slow rate (1.4 and 0.5%, respectively).
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 4.
Observed values (circles) and estimated means and 95%
confidence intervals (bars) for EA-D expression in viable cells only
following induction of latent EBV in Raji cells and X50-7 cells growing
at a slow rate and a fast rate with TPA (20 ng/ml),
n-butyrate (4 mM), or both compounds measured by FACS
analysis at 4 days. The combination of TPA plus n-butyrate
resulted in a synergistic induction of latent EBV as evidenced by the
marked decrease in cell viability (Fig. 1) and the increased level of
EA-D production in viable cells.
|
|
For X50-7 cells (Fig. 2), the highest levels of EA-D by FACS analysis
(viable cells only) were found in untreated cells (11.3 to 23.3%) and
fell dramatically with treatment with TPA (1.3 to 8.4%),
n-butyrate (0.6 to 1.0%), or both chemicals (0.2 to 1.4%).
Comparison of immunofluorescence microscopy (viable and nonviable
cells) and FACS analysis (viable cells only) methods for EA-D detection
and quantitation revealed generally higher levels by FACS analysis,
with greater disparity between the methods for cell populations
demonstrating higher EA-D levels (Table
1). The fluorescence intensity by FACS
analysis of Raji cells showed a bimodal distribution that was most
apparent for the cell populations with the highest EA-D levels (Fig.
2). The only substantial discordance between the two methods was in the
results for EA-D levels in untreated X50-7 cells, with no discernible
EA-D expression by visual immunofluorescence microscopy compared to
11.3 to 23.3% EA-D expression by FACS analysis. The fluorescence
intensity of the untreated X50-7 cells determined by FACS analysis
showed a platykurtic distribution compared to that of untreated Raji
cells (Fig. 2).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Expression of EA-D determined by immunofluorescence of
viable and nonviable cells and by FACS analysis of only viable cells in
Raji and X50-7 cells after chemical induction of EBV with TPA,
n-butyrate, and both chemicals at 2 and
4 daysa
|
|
 |
DISCUSSION |
The effects of chemical induction for the reduction of cell
viability were much greater for X50-7 cells than for Raji cells (Fig.
1). Chemical induction of the strain of EBV in Raji cells results in
the production of EAs but without the progression to viral replication
and consequent cell death (32, 43). The substantially higher
levels of EA-D present in Raji cells at 4 days compared to the levels
at 2 days and compared to the levels in X50-7 cells at 4 days was the
result of additional induction of latent EBV resulting in the
accumulation of intact cells producing EA-D but without progression to
viral replication and cell death (32, 43). It is not clear
whether EA induction in Raji cells is lethal or hastens cell death
(1, 2, 39). The decreased viability of Raji cells following
chemical induction is more likely due to direct chemical toxicity
rather than cell death resulting from virus replication. Unlike Raji
cells, chemical induction of EBV replication in cell lines such as
X50-7 results in increased cell death from lytic viral replication, and
therefore, the efficiency of chemical induction of EBV replication in
X50-7 cells is indicated by decreased cell viability (Fig. 1) rather
than increased levels of EA-D expression in intact cells (Fig. 4). The
viability of X50-7 cells after chemical induction, as determined by
FACS analysis, compared to the viability of P3HR-1 cells (another
EBV-producing cell line), as determined by trypan blue exclusion
(40), showed the same trends but markedly lower levels by
FACS analysis. This may represent some difference in these two
EBV-producing cell lines but is more likely the result of
methodological differences.
In X50-7 cells EA-D expression is characteristically followed by lytic
viral replication and cell death; examination of only the viable cells
demonstrates an apparent decrease in the percentage of EA-D expression
in this population (Table 1) since those cells initially expressing
even low levels of EA-D progress to lysis after induction. The
differences between immunofluorescence microscopy and FACS analysis of
cells expressing EA-D after chemical induction results from this
biologic difference of Raji and X50-7 cells and the inclusion of viable
and nonviable cells for immunofluorescence microscopy analysis but the
inclusion of only viable cells by FACS analysis.
Treatment with the combination of TPA and n-butyrate
resulted in greater decreases in cell viability in both cell lines
(Fig. 1) and a significantly higher percentage of Raji cells expressing EA-D (Fig. 4). The synergistic action of n-butyrate and TPA
for EA-D expression demonstrated by these results is consistent with the observations of other investigators (31).
Raji cells growing at a slow or a fast rate demonstrated similar
patterns of viability, but with significant differences in the
magnitude of cell death, and similar levels of EA-D expression. The
X50-7 cells growing at a slow or a fast rate demonstrated similar
results with regard to cell viability and EA-D expression.
The results of conventional immunofluorescence microscopy and FACS
analysis of EA-D expression in Raji cells are internally consistent and
are in close agreement. No constitutive EA-D expression was observed by
immunofluorescence microscopy for untreated Raji cells, although low
levels (
= 0.45%) were detected by FACS analysis.
The greatest discrepancy between these methods observed with Raji cells
was for the treatment group with the highest level of EA-D expression.
This was observed at 4 days for cells treated with both chemicals, with
the level of EA-D expression being 6.9 to 11.5%
(
= 9.2%) by visual immunofluorescence
microscopy compared to 18.7 to 24.5% (
= 21.6%) by
FACS analysis (Table 1). The difference between these two techniques is
due to the greater sensitivity of FACS analysis for the detection of
EA-D at lower levels of expression, most likely resulting from the
difficulty of visually discerning, despite the use of very experienced
observers, weakly positive cells by immunofluorescence microscopy. This
is especially problematic in the visual interpretation of cell smears with significant background fluorescence.
The greatest discrepancy between FACS analysis and visual
immunofluorescence microscopy was EA-D expression by untreated X50-7 cells (
values, 18.4 and 0%, respectively).
Comparison of the fluorescence curves obtained by FACS analysis
demonstrates that untreated X50-7 cells have a platykurtic distribution
compared to that for untreated Raji cells (Fig. 2) and suggests that in X50-7 cells and perhaps other EBV-producing cell lines there may be
ultralow levels of EA-D present that are detectable by FACS analysis
but that are not discernible by conventional visual immunofluorescence microscopy. The low- or intermediate-level transcriptional activity that has been demonstrated for almost the entire EBV genome during latency (23) supports this possibility and suggests that
FACS analysis may be more sensitive than conventional methods for the detection of ultralow levels of EBV protein production. This may not be
detectable by immunofluorescence microscopy due to the inability to
visually discern slightly positive cells in cell smears with
significant background fluorescence. The levels of EA-D in X50-7 cells
following chemical induction are equivalent by visual microscopy and
FACS analysis. This scenario probably represents induction of EBV in
the population of the cells expressing ultralow levels of EA-D detected
initially only by FACS analysis, with the ultimate culmination in the
death of these induced cells and their subsequent exclusion from FACS
analysis, which included only viable cells. In support of this
interpretation is the difference between the levels of EA-D expression
between untreated Raji cells and X50-7 cells at 4 days of approximately
19.0% and the difference in cell viability between untreated Raji
cells and X50-7 cells at 4 days of 22.5%. The X50-7 cells with
ultralow levels of EA-D, which are indiscernible by conventional
immunofluorescence methods but which are detectable by FACS analysis,
may indicate a primed viral state with greater susceptibility for virus
induction.
Both visual immunofluorescence microscopy (of all cells) and FACS
analysis (of viable cells only) demonstrated significant differences in
EA-D expression between Raji cells and X50-7 cells. FACS analysis also
detected in untreated X50-7 cells EA-D that was not detected by
conventional immunofluorescence microscopy. It is likely that study of
additional EBV-infected cell lines by FACS analysis may demonstrate
even among producer cell lines differences that are less apparent by
conventional methods.
The application of FACS analysis in the study of viral protein
expression has demonstrated several advantages. FACS analysis facilitates the evaluation of much larger cell sample sizes (20,000 to
100,000 cells) than is routinely feasible by immunofluorescence microscopy. FACS analysis is also more objective and does not require
experience and expertise in interpretating the visual appearance of the
cells. This could minimize intra- and interlaboratory variability and
improve experimental reproducibility. FACS analysis may be more
sensitive than visual immunofluorescence microscopy for the detection
of ultralow levels of protein and may facilitate correct identification
of negative cells when moderate or high levels of protein are present
in a significant portion of cells.
The increased sensitivity and increased reproducibility of FACS
analysis facilitate the study of viral biology by permitting the
selection of only viable cells and also the quantitative determination of viral protein production at different stages of latency and replication. The application of FACS analysis to these biologic questions requires an understanding of the differences in the biology
between EBV strains, differences resulting from the method of
induction, and possible differences due to growth conditions of the
cells prior to induction. The platykurtic distribution of EA-D in
untreated X50-7 cells compared to that in Raji cells and the
constitutive block in Raji cells that prevents viral DNA synthesis and
the production of late EBV gene products indicate the better
suitability of Raji cells for studies of EA-D induction by FACS
analysis. In these experiments the use of FACS analysis to demonstrate
induction of latent EBV in Raji cells by detection of EA-D expression
in Raji cells was more sensitive than the use of immunofluorescence
microscopy. This suggests that FACS analysis of Raji cells may also be
the method of choice for the study of compounds with an unknown or a
potentially weak potential to chemically induce latent EBV.
 |
ACKNOWLEDGMENTS |
This work was supported by grants 0389 and 0200 from the
Smokeless Tobacco Research Council and a support grant (5P30 CA54174) to the San Antonio Cancer Center from the National Cancer Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pediatrics, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78284-7811. Phone: (210) 567-5301. Fax: (210) 567-6921. E-mail: jenson{at}uthscsa.edu.
 |
REFERENCES |
| 1.
|
Anisimová, E.,
K. Prachová,
J. Roubal, and V. Vonka.
1984.
Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation.
Arch. Virol.
81:223-237[Medline].
|
| 2.
|
Anisimová, E.,
A. K. Saemundsen,
J. Roubal,
V. Vonka, and G. Klein.
1982.
Effects of n-butyrate on Epstein-Barr virus-carrying lymphoma lines.
J. Gen. Virol.
58:163-171[Abstract/Free Full Text].
|
| 3.
|
Baer, R.,
A. T. Bankier,
M. D. Biggin,
P. L. Deininger,
P. J. Farrell,
T. J. Gibson,
G. Hatfull,
G. S. Hudson,
S. C. Satchwell,
C. Séguin,
P. S. Tuffnell, and B. G. Barrell.
1984.
DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
Nature
310:207-211[Medline].
|
| 4.
|
Benz, W. C.,
P. J. Siegel, and J. Baer.
1978.
Effects of adenine arabinoside on lymphocytes infected with Epstein-Barr virus.
J. Virol.
27:475-482[Abstract/Free Full Text].
|
| 5.
|
Bister, K.,
N. Yamamoto, and H. zur Hausen.
1979.
Differential inducibility of Epstein-Barr virus in cloned, non-producer Raji cells.
Int. J. Cancer
23:818-825[Medline].
|
| 6.
|
Blacklow, N. R.,
B. K. Watson,
G. Miller, and B. M. Jacobson.
1971.
Mononucleosis with heterophil antibodies and EB virus infection. Acquisition by an elderly patient in hospital.
Am. J. Med.
51:549-552[Medline].
|
| 7.
|
Boos, H.,
R. Berger,
C. Kuklik-Roos,
T. Iftner, and N. Mueller-Lantzsch.
1987.
Enhancement of Epstein-Barr virus membrane protein (LMP) expression by serum, TPA, or n-butyrate in latently infected Raji cells.
Virology
159:161-165[Medline].
|
| 8.
|
Bouvier, G.,
S. Poirier,
Y. M. Shao,
C. Malaveille,
H. Ohshima,
A. Polack,
G. W. Bornkamm,
Y. Zeng,
G. de-Thé, and H. Bartsch.
1991.
Epstein-Barr virus activators, mutagens and volatile nitrosamines in preserved food samples from high-risk areas for nasopharyngeal carcinoma.
IARC Sci. Publ.
105:204-209.
|
| 9.
|
Cook, I. D.,
F. Shanahan, and P. J. Farrell.
1994.
Epstein-Barr virus SM protein.
Virology
205:217-227[Medline].
|
| 10.
|
Countryman, J.,
H. Jenson,
R. Seibl,
H. Wolf, and G. Miller.
1987.
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency.
J. Virol.
61:3672-3679[Abstract/Free Full Text].
|
| 11.
|
Decaussin, G.,
V. Leclerc, and T. Ooka.
1995.
The lytic cycle of Epstein-Barr virus in the nonproducer Raji line can be rescued by the expression of a 135-kilodalton protein encoded by the BALF2 open reading frame.
J. Virol.
69:7309-7314[Abstract].
|
| 12.
|
Epstein, M. A.,
B. G. Achong,
Y. M. Barr,
B. Zajac,
G. Henle, and W. Henle.
1966.
Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).
J. Natl. Cancer Inst.
37:547-559.
|
| 13.
|
Flemington, E., and S. H. Speck.
1990.
Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1.
J. Virol.
64:1217-1226[Abstract/Free Full Text].
|
| 14.
|
Gerber, P.
1972.
Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells.
Proc. Natl. Acad. Sci. USA
69:83-85[Abstract/Free Full Text].
|
| 15.
|
Hammerschmidt, W., and B. Sugden.
1988.
Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus.
Cell
55:427-433[Medline].
|
| 16.
|
Hampar, B.,
J. G. Derge,
L. M. Martos, and J. L. Walker.
1971.
Persistence of a repressed Epstein-Barr virus genome in Burkitt lymphoma cells made resistant to 5-bromodeoxyuridine.
Proc. Natl. Acad. Sci. USA
68:3185-3189[Abstract/Free Full Text].
|
| 17.
|
Hatfull, G.,
A. T. Bankier,
B. G. Barrell, and P. J. Farrell.
1988.
Sequence analysis of Raji Epstein-Barr virus DNA.
Virology
164:334-340[Medline].
|
| 18.
|
Hayashi, K.
1992.
Effect of protein kinase C inhibitors with different action mechanisms on Epstein-Barr virus replication.
Intervirology
33:217-224[Medline].
|
| 19.
|
Henle, W.,
G. Henle,
B. A. Zajac,
G. Pearson,
R. Waubke, and M. Scriba.
1970.
Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.
Science
169:188-190[Abstract/Free Full Text].
|
| 20.
|
Jenson, H. B.,
Y. Ench, and C. V. Sumaya.
1997.
Epstein-Barr virus, p. 634-643.
In
N. R. Rose, E. C. de Macario, H. Folds, H. C. Lane, and R. M. Nakamura (ed.), Manual of clinical laboratory immunology, 5th ed. American Society for Microbiology, Washington, D.C.
|
| 21.
|
Kallin, B.,
J. Luka, and G. Klein.
1979.
Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells.
J. Virol.
32:710-716[Abstract/Free Full Text].
|
| 22.
|
Kiehl, A., and D. I. Dorsky.
1995.
Bipartite DNA-binding region of the Epstein-Barr virus BMRF1 product essential for DNA polymerase accessory function.
J. Virol.
69:1669-1677[Abstract].
|
| 23.
|
Kirchner, E. A.,
G. W. Bornkamm, and A. Polack.
1991.
Transcriptional activity across the Epstein-Barr virus genome in Raji cells during latency and after induction of an abortive lytic cycle.
J. Gen. Virol.
72:2391-2398[Abstract/Free Full Text].
|
| 24.
|
Laux, G.,
U. K. Freese,
R. Fischer,
A. Polack,
E. Kofler, and G. W. Bornkamm.
1988.
TPA-inducible Epstein-Barr virus genes in Raji cells and their regulation.
Virology
162:503-507[Medline].
|
| 25.
|
Lee, W.,
P. Mitchell, and R. Tjian.
1987.
Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements.
Cell
49:741-752[Medline].
|
| 26.
|
Levitt, D., and M. King.
1987.
Methanol fixation permits flow cytometric analysis of immunofluorescent stained intracellular antigens.
J. Immunol. Methods
96:233-237[Medline].
|
| 27.
|
Loken, M. R., and L. A. Herzenberg.
1975.
Analysis of cell populations with a fluorescence-activated cell sorter.
Ann. N. Y. Acad. Sci.
254:163-171[Medline].
|
| 28.
|
Luka, J.,
B. Kallin, and G. Klein.
1979.
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.
Virology
94:228-231[Medline].
|
| 29.
|
Miller, G.,
M. Rabson, and L. Heston.
1984.
Epstein-Barr virus with heterogeneous DNA disrupts latency.
J. Virol.
50:174-182[Abstract/Free Full Text].
|
| 30.
|
Nonoyama, M., and J. S. Pagano.
1972.
Separation of Epstein-Barr virus DNA from large chromosomal DNA in non-virus-producing cells.
Nature New Biol.
238:169-171[Medline].
|
| 31.
|
Nutter, L. M.,
S. P. Grill,
J. S. Li,
R. S. Tan, and Y. C. Cheng.
1987.
Induction of virus enzymes by phorbol esters and n-butyrate in Epstein-Barr virus genome-carrying Raji cells.
Cancer Res.
47:4407-4412[Abstract/Free Full Text].
|
| 32.
|
Ooka, T.,
G. M. Lenoir,
G. Decaussin,
G. W. Bornkamm, and J. Daillie.
1986.
Epstein-Barr virus-specific DNA polymerase in virus-nonproducer Raji cells.
J. Virol.
58:671-675[Abstract/Free Full Text].
|
| 33.
|
Parker, B. D.,
A. Bankier,
S. Satchwell,
B. Barrell, and P. J. Farrell.
1990.
Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region.
Virology
179:339-346[Medline].
|
| 34.
|
Pearson, G. R.,
B. Vroman,
B. Chase,
T. Sculley,
M. Hummel, and E. Kieff.
1983.
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies.
J. Virol.
47:193-201[Abstract/Free Full Text].
|
| 35.
|
Polack, A.,
H. Delius,
U. Zimber, and G. W. Bornkamm.
1984.
Two deletions in the Epstein-Barr virus genome of the Burkitt lymphoma nonproducer line Raji.
Virology
133:146-157[Medline].
|
| 36.
|
Pritchett, R.,
M. Pendersen, and E. Kieff.
1976.
Complexity of EBV homologous DNA in continuous lymphoblastoid cell lines.
Virology
74:227-231[Medline].
|
| 37.
|
Pulvertaft, R. J. V.
1965.
A study of malignant tumours in Nigeria by short-term tissue culture.
J. Clin. Pathol.
18:261-273.
|
| 38.
|
Raab-Traub, N.,
T. Dambaugh, and E. Kieff.
1980.
DNA of Epstein-Barr virus. VII. B95-8, the previous prototype, is an unusual deletion derivative.
Cell
22:257-267[Medline].
|
| 39.
|
Roubal, J., and K. Roubalová.
1985.
Effect of n-butyrate on superinfection of Raji lymphoblastoid cell line by Epstein-Barr virus.
Acta Virol.
29:162-165[Medline].
|
| 40.
|
Sairenji, T.,
R. C. Spiro, and R. E. Humphreys.
1984.
Differential effect of TPA and n-butyrate on induction of li and EBV antigens in the P3HR-1 lymphoblastoid cell line.
Hematol. Oncol.
2:381-389[Medline].
|
| 41.
|
Sokal, R. R., and F. J. Rohlf.
1987.
Introduction to biostatistics. W. H.
Freeman & Co., New York, N.Y.
|
| 42.
|
Takada, K.
1984.
Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines.
Int. J. Cancer
33:27-32[Medline].
|
| 43.
|
Tan, R. S.,
J. S. Li,
S. P. Grill,
L. M. Nutter, and Y. C. Cheng.
1986.
Demonstration of Epstein-Barr virus-specific DNA polymerase in chemically induced Raji cells and its antibody in serum from patients with nasopharyngeal carcinoma.
Cancer Res.
46:5024-5028[Abstract/Free Full Text].
|
| 44.
|
Tovey, M. G.,
G. Lenoir, and J. Begon-Lours.
1978.
Activation of latent Epstein-Barr virus by antibody to human IgM.
Nature
276:270-272[Medline].
|
| 45.
|
Tsurumi, T.,
T. Daikoku, and Y. Nishiyama.
1994.
Further characterization of the interaction between the Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit with regard to the 3'-to-5' exonucleolytic activity and stability of initiation complex at primer terminus.
J. Virol.
68:3354-3363[Abstract/Free Full Text].
|
| 46.
|
Wilson, G., and G. Miller.
1979.
Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants.
Virology
95:351-358[Medline].
|
| 47.
|
Wong, K. M., and A. J. Levine.
1989.
Characterization of proteins encoded by the Epstein-Barr virus transactivator gene BMLF1.
Virology
168:101-111[Medline].
|
| 48.
|
Zhang, C. X.,
G. Decaussin,
J. Daillie, and T. Ooka.
1988.
Altered expression of two Epstein-Barr virus early genes localized in BamHI-A in nonproducer Raji cells.
J. Virol.
62:1862-1869[Abstract/Free Full Text].
|
| 49.
|
Zimber, U.,
H. K. Adldinger,
G. M. Lenoir,
M. Vuillaume,
M. V. Knebel-Doeberitz,
G. Laux,
C. Desgranges,
P. Wittmann,
U. K. Freese,
U. Schneider, and G. W. Bornkamm.
1986.
Geographical prevalence of two types of Epstein-Barr virus.
Virology
154:56-66[Medline].
|
| 50.
|
zur Hausen, H.,
F. J. O'Neill,
U. K. Freese, and E. Hecker.
1978.
Persisting oncogenic herpesvirus induced by the tumour promoter TPA.
Nature
272:373-375[Medline].
|
Clinical and Diagnostic Laboratory Immunology, January 1998, p. 91-97, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Poirier-Toulemonde, A.-S., Milpied, N., Cantarovich, D., Morcet, J.-F., Billaudel, S., Imbert-Marcille, B.-M.
(2000). Clinical Relevance of Direct Quantification of pp65 Antigenemia Using Flow Cytometry in Solid Organ and Stem Cell Transplant Recipients. J. Clin. Microbiol.
38: 3143-3149
[Abstract]
[Full Text]
-
Imbert-Marcille, B.-M., Coste-Burel, M., Robillard, N., Foucaud-Gamen, J., Billaudel, S., Drouet, E.
(2000). Sequential Use of Paraformaldehyde and Methanol as Optimal Conditions for the Direct Quantification of ZEBRA and Rta Antigens by Flow Cytometry. CVI
7: 206-211
[Abstract]
[Full Text]